'Absurd' To Argue PTAB Wins Bar Patent Cases: Generics Cos.

Law360 (February 19, 2019, 10:44 PM EST) -- The America Invents Act doesn't stop patent challengers who won at the Patent Trial and Appeal Board from pursuing their winning arguments in court, and blocking that judicial path would lead to "absurd results," a group of generic-drug makers told the Federal Circuit on Tuesday.

The generics makers, including Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC, took aim at the contentious interpretation of the AIA's estoppel provision in a Tuesday filing that urged the Federal Circuit to uphold a lower court's invalidation of patents on the cancer drug Zytiga held by Johnson & Johnson unit Janssen Biotech Inc.

Barring patent challengers...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!